v3.25.4
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Mar. 10, 2026
Jun. 30, 2025
Cover [Abstract]        
Entity Registrant Name PLUS THERAPEUTICS, INC.      
Entity Central Index Key 0001095981      
Trading Symbol PSTV      
Current Fiscal Year End Date --12-31      
Entity Well-known Seasoned Issuer No      
Entity Voluntary Filers No      
Entity Interactive Data Current Yes      
Entity Current Reporting Status Yes      
Entity Filer Category Non-accelerated Filer      
Entity Public Float       $ 31.9
Entity Common Stock, Shares Outstanding     171,550,698  
Document Fiscal Year Focus 2025      
Document Fiscal Period Focus FY      
Document Type 10-K      
Amendment Flag false      
Document Period End Date Dec. 31, 2025      
Entity Shell Company false      
Entity Small Business true      
Entity Emerging Growth Company false      
ICFR Auditor Attestation Flag false      
Document Financial Statement Error Correction [Flag] false      
Title of 12(b) Security Common Stock, par value $0.001 per share      
Security Exchange Name NASDAQ      
Entity File Number 001-34375      
Entity Incorporation, State or Country Code DE      
Entity Tax Identification Number 33-0827593      
Entity Address, Address Line One 6420 LEVIT GREEN BOULEVARD      
Entity Address, Address Line Two SUITE 310      
Entity Address, City or Town HOUSTON      
Entity Address, State or Province TX      
Entity Address, Postal Zip Code 77021      
City Area Code 737      
Local Phone Number 255-7194      
Document Annual Report true      
Document Transition Report false      
Auditor Firm ID 199 243    
Auditor Name CBIZ CPAs P.C. BDO USA P.C.    
Auditor Location New York, NY Austin, Texas    
Auditor Opinion

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Plus Therapeutics, Inc. (the “Company”) as of December 31, 2025, the related consolidated statements of operations, stockholders’ equity (deficit) and cash flows for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, based on our audit, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheet of Plus Therapeutics, Inc. (the “Company”) as of December 31, 2024, the related consolidated statement of operations, stockholders’ equity (deficit), and cash flows for the year then ended and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

      
Documents Incorporated by Reference [Text Block]

Portions of the registrant’s definitive proxy statement for its 2026 Annual Meeting of Stockholders, which will be filed with the United States Securities and Exchange Commission within 120 days of December 31, 2025, are incorporated by reference into Part III of this Annual Report on Form 10-K.